Forte Biosciences Inc
FBRX6.050USD
-0.830-12.06%
Handelsschluss 04/23, 16:00（ET）Kurse um 15 Minuten verzögert
38.68MMarktkapitalisierung
VerlustKGV TTM
mehr Informationen über Forte Biosciences Inc Unternehmen
Forte Biosciences, Inc. is a clinical-stage biopharmaceutical company that is advancing FB102, which is an anti-CD122 monoclonal antibody therapeutic candidate with potentially broad autoimmune and autoimmune-related indications. It is advancing clinical development of FB102 into patient-based trials for celiac disease and non-segmental vitiligo. The Company's FB102 program focuses on addressing key pathways implicated in these indications with a CD122 antagonist. CD122 is a subunit of IL-2/IL-15 receptors which are key regulators of NK cells and certain T cell subsets. FB102 has potentially other autoimmune and autoimmune-related applications including vitiligo, alopecia areata, and type 1 diabetes (T1D). Its subsidiaries include Forte Subsidiary, Inc. and Forte Biosciences Australia Proprietary Limited.
Unternehmensinformationen
Unternehmens-codeFBRX
Name des UnternehmensForte Biosciences Inc
IPO-datumApr 13, 2017
Gegründet am2007
CEODr. Paul A. Wagner, Ph.D.
Anzahl der mitarbeiter14
WertpapierartOrdinary Share
GeschäftsjahresendeApr 13
Addresse- -
Stadt- -
BörseNASDAQ Capital Market Consolidated
Land- -
Postleitzahl- -
Telefon- -
Website- -
Unternehmens-codeFBRX
IPO-datumApr 13, 2017
Gegründet am2007
Führungskräfte
Name
Name/Position
Position
Aktienbesitz
Veränderung
Dr. Paul A. Wagner, Ph.D.
Dr. Paul A. Wagner, Ph.D.
Chairman of the Board, President, Chief Executive Officer
Chairman of the Board, President, Chief Executive Officer
79.79K
+1.57%
Mr. Antony A. Riley
Mr. Antony A. Riley
Chief Financial Officer
Chief Financial Officer
31.22K
+0.71%
Mr. David W. (Dave) Gryska
Mr. David W. (Dave) Gryska
Independent Director
Independent Director
5.94K
-0.02%
Mr. Steven Kornfeld
Mr. Steven Kornfeld
Independent Director
Independent Director
3.96K
--
Dr. Stephen K. Doberstein, Ph.D.
Dr. Stephen K. Doberstein, Ph.D.
Independent Director
Independent Director
--
--
Mr. Richard G. (Rich) Vincent, CPA
Mr. Richard G. (Rich) Vincent, CPA
Independent Director
Independent Director
--
--
Mr. Shiv Kapoor
Mr. Shiv Kapoor
Independent Director
Independent Director
--
--
Dr. Barbara K. Finck, M.D.
Dr. Barbara K. Finck, M.D.
Independent Director
Independent Director
--
--
Dr. Scott C. Brun, M.D.
Dr. Scott C. Brun, M.D.
Independent Director
Independent Director
--
--
Name
Name/Position
Position
Aktienbesitz
Veränderung
Dr. Paul A. Wagner, Ph.D.
Dr. Paul A. Wagner, Ph.D.
Chairman of the Board, President, Chief Executive Officer
Chairman of the Board, President, Chief Executive Officer
79.79K
+1.57%
Mr. Antony A. Riley
Mr. Antony A. Riley
Chief Financial Officer
Chief Financial Officer
31.22K
+0.71%
Mr. David W. (Dave) Gryska
Mr. David W. (Dave) Gryska
Independent Director
Independent Director
5.94K
-0.02%
Mr. Steven Kornfeld
Mr. Steven Kornfeld
Independent Director
Independent Director
3.96K
--
Dr. Stephen K. Doberstein, Ph.D.
Dr. Stephen K. Doberstein, Ph.D.
Independent Director
Independent Director
--
--
Mr. Richard G. (Rich) Vincent, CPA
Mr. Richard G. (Rich) Vincent, CPA
Independent Director
Independent Director
--
--
Umsatzaufteilung
Keine Daten
Keine Daten
Nach Geschäftsbereich
Nach Region
Keine Daten
Aktionäre
Update-Zeit: Fri, Mar 7
Update-Zeit: Fri, Mar 7
Aktionärsstatistik
Art
Aktionärsstatistik
Aktionäre
Anteil
Fred Alger Management, LLC
17.23%
Janus Henderson Investors
10.49%
Tybourne Capital Management (HK) Limited
9.42%
Ikarian Capital LLC
9.26%
OrbiMed Advisors, LLC
9.12%
Other
44.48%
Aktionärsstatistik
Aktionäre
Anteil
Fred Alger Management, LLC
17.23%
Janus Henderson Investors
10.49%
Tybourne Capital Management (HK) Limited
9.42%
Ikarian Capital LLC
9.26%
OrbiMed Advisors, LLC
9.12%
Other
44.48%
Art
Aktionäre
Anteil
Investment Advisor/Hedge Fund
34.31%
Hedge Fund
32.39%
Private Equity
10.57%
Corporation
7.46%
Individual Investor
1.98%
Investment Advisor
0.19%
Research Firm
0.09%
Other
13.00%
Institutionelle Beteiligung
Update-Zeit: Mon, Mar 3
Update-Zeit: Mon, Mar 3
Berichtszeitraum
Anzahl der Institutionen
Gehaltenen Aktien
Anteil
Veränderung
2025Q1
76
5.72M
86.97%
+3.22M
2024Q4
82
5.78M
90.44%
+3.18M
2024Q3
72
948.15K
58.94%
-63.60K
2024Q2
79
972.89K
60.86%
-40.06K
2024Q1
108
982.74K
67.53%
-37.22K
2023Q4
121
973.92K
67.03%
-54.29K
2023Q3
139
1.01M
71.78%
+97.73K
2023Q2
175
455.32K
54.14%
-352.22K
2023Q1
185
468.85K
56.07%
-1.69M
2022Q4
191
415.29K
49.70%
-1.75M
Mehr Anzeigen
Aktionärsaktivitäten
Name
Gehaltenen Aktien
Anteil
Veränderung
Änderung%
Datum
Fred Alger Management, LLC
1.13M
17.23%
+175.02K
+18.25%
Dec 31, 2024
Janus Henderson Investors
690.74K
10.49%
+690.74K
--
Dec 31, 2024
Tybourne Capital Management (HK) Limited
619.98K
9.42%
+475.00K
+327.63%
Dec 31, 2024
Ikarian Capital LLC
609.23K
9.26%
+609.23K
--
Dec 31, 2024
OrbiMed Advisors, LLC
600.00K
9.12%
+510.00K
+566.67%
Dec 31, 2024
BVF Partners L.P.
594.28K
9.03%
+475.00K
+398.22%
Dec 31, 2024
Nemean Asset Management, LLC
432.28K
6.57%
--
--
Dec 30, 2024
Cable Car Capital LLC
219.60K
3.34%
+138.32K
+170.19%
Dec 31, 2024
Woodline Partners LP
204.28K
3.1%
+204.28K
--
Dec 31, 2024
Perceptive Advisors LLC
95.74K
1.45%
--
--
Dec 31, 2024
Mehr Anzeigen
Verbundene ETFs
Update-Zeit: Sun, Apr 6
Update-Zeit: Sun, Apr 6
Name
Anteil
Fidelity Nasdaq Composite Index ETF
0%
iShares Core S&P Total U.S. Stock Market ETF
0%
Fidelity Nasdaq Composite Index ETF
Anteil0%
iShares Core S&P Total U.S. Stock Market ETF
Anteil0%
Dividende
In den vergangenen 5 Jahren wurden insgesamt
0.00
USD an Dividenden ausgeschüttet.
Datum
Dividende
Stichtag für die Aktienregistrierung
Zahltag
Ex-Dividendentag
Keine Daten
Aktien-Split
Datum
Art
Verhältnis
Aug 22, 2024
Merger
25<1
Aug 22, 2024
Merger
25<1
Aug 22, 2024
Merger
25<1
Aug 22, 2024
Merger
25<1
Jun 15, 2020
Merger
15<1
Jun 15, 2020
Merger
15<1
Datum
Art
Verhältnis
Aug 22, 2024
Merger
25<1
Aug 22, 2024
Merger
25<1
Aug 22, 2024
Merger
25<1
Aug 22, 2024
Merger
25<1
Jun 15, 2020
Merger
15<1
Jun 15, 2020
Merger
15<1
Jun 15, 2020
Merger
15<1
Jun 15, 2020
Merger
15<1